Mode
Text Size
Log in / Sign up
N/A N=42

Effect of Levodopa on Postural Motor Learning in Parkinson Disease

Parkinson Disease

Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Feb 2017
Primary outcome: Primary: Change in Movement of Center of Mass (COM) After Postural Perturbation — 0.31; 0.28; 0.32; 0.26 meters

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Postural perturbation (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Jan 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Movement of Center of Mass (COM) After Postural Perturbation
0.31; 0.28; 0.32; 0.26; 0.23; 0.31
PRIMARY
Change in Steps After Postural Perturbation
2.22; 2.03; 2.09; 1.92; 1.15; 2.05
SECONDARY
Change in First Step Length
0.18; 0.25; 0.21; 0.20; 0.27; 0.21
SECONDARY
Cortical Excitability
40.57; 40.71

Summary

The primary goal of this project is to gain a better understanding of whether and how levodopa (a common anti-Parkinson disease medication) alters postural motor learning in people with Parkinson disease. A secondary goal is to assess whether motor cortical excitability, measured via Transcranial magnetic stimulation, is related to postural motor learning. Participants with Parkinson disease will complete between 50 and 100 postural perturbations (via support surface translations), ON and OFF their dopamine replacement therapy (i.e. levodopa). Adaptation of responses to these perturbations will be tracked. Participants will also undergo transcranial magnetic stimulation to capture cortical excitability of the brain (in particular the motor cortex). Cortical excitability will be correlated to adaptation of stepping (i.e. postural motor learning) ON and OFF levodopa. Investigators will also capture postural motor learning and cortical excitability in age-matched healthy adults. Investigators hypothesize that dopamine will have a negative effect on postural motor learning, and the cortical excitability will be correlated to postural motor learning.

Eligibility Criteria

Inclusion Criteria

  • Between 18 and 90 years of age.
  • Individuals with Parkinson Disease
  • Healthy adults age-matched to PD participants
  • Participants with PD will be currently taking dopamine replacement (i.e. Levodopa)

Exclusion Criteria

All subjects exclusion criteria:

  • Deep brain stimulation
  • Recent (within 6 months) orthopedic injuries influencing standing or balance
  • Inability to stand independently

Transcranial magnetic stimulation exclusion criteria (for the subset of individuals taking part in the Transcranial Magnetic Stimulation portion of the study):

  • History of epilepsy or currently taking any epileptic medication,
  • History of seizures
  • Family history of epilepsy or seizures
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02239978). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search